References
- International Agency for Research on Cancer WHO. Cancer today. Available from: https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%255B10%252C0%255D2020. Accessed September 17, 2023.
- Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
- Xu J. Trends in liver cancer mortality among adults aged 25 and over in the United States, 2000–2016. NCHS Data Brief. 2018;2018(314):1–8.
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
- Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
- Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1(2):156–164. doi:10.1016/S2468-1253(16)30018-8
- Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–838. doi:10.1002/hep.28368
- Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
- Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
- Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. doi:10.1111/j.1365-2036.2009.04014.x
- Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624
- Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–422. doi:10.1007/s00432-004-0552-0
- Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1016/j.jhep.2019.08.025
- Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–269. doi:10.7326/M14-0558
- El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60(7):992–997. doi:10.1136/gut.2010.230508
- Choi DT, Kum HC, Park S, et al. Hepatocellular Carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976–87.e4. doi:10.1016/j.cgh.2018.10.031
- Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved survival in patients with viral hepatitis-induced Hepatocellular Carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a Population-Based Retrospective Cohort Study. PLoS One. 2015;10(9):e0138907. doi:10.1371/journal.pone.0138907
- Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting.What can we learn from clinical practice? Liver Int. 2015;35(7):1862–1871. doi:10.1111/liv.12764
- SweLiv. Swedish registry of tumors in the liver and bile ducts. Annual Report 2022; 2022. Available from: https://cancercentrum.se/globalassets/cancerdiagnoser/lever-och-galla/kvalitetsregister/sweliv_patientrapport2021.pdf. Accessed September 14, 2023.
- Henriksson M, Björnsson B, Sternby Eilard M, et al. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4(1):109–117. doi:10.1002/bjs5.50226
- Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168(1):98–104. doi:10.1093/aje/kwn120
- Cucchetti A, Trevisani F, Pecorelli A, et al. Estimation of lead- time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61(2):333–341. doi:10.1016/j.jhep.2014.03.037
- Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–139. doi:10.1016/j.jhep.2022.01.023
- Lang S, Martin A, Kasper P, et al. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol. 2020;55(2):222–227. doi:10.1080/00365521.2020.1718747
- Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53(2):291–297. doi:10.1016/j.jhep.2010.03.010
- Kim HY, Nam JY, Lee JH, et al. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther. 2018;47(11):1490–1501. doi:10.1111/apt.14623
- van Meer S, de Man RA, Coenraad MJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63(5):1156–1163. doi:10.1016/j.jhep.2015.06.012
- Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14(6):1272–1294. doi:10.1002/1097-0142(196111/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H
- Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28(5):783–793. doi:10.1016/j.bpg.2014.08.008
- Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54(6):1998–2004. doi:10.1002/hep.24581
- Demirtas CO, Gunduz F, Tuney D, et al. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32(4):517–523. doi:10.1097/MEG.0000000000001528
- Demirtas CO, Ozdogan OC. Surveillance of hepatocellular carcinoma in cirrhotic patients: current knowledge and future directions. Hepatol Forum. 2020;1(3):112–118. doi:10.14744/hf.2020.2020.0003
- Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for Hepatocellular Carcinoma surveillance in high-risk patients with cirrhosis. Hepatology. 2019;69(4):1599–1613. doi:10.1002/hep.30330
- Moon AM, Weiss NS, Beste LA, et al. No association between screening for Hepatocellular Carcinoma and reduced cancer-related mortality in patients with cirrhosis. Gastroenterology. 2018;155(4):1128–39.e6. doi:10.1053/j.gastro.2018.06.079
- International Agency for Research on Cancer WHO. Cancer today. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf2020. Accessed September 7, 2023.
- Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;52(4):701–709. doi:10.1111/apt.15917